Philip H Smith1,2,3, Andrea H Weinberger4,5, Ju Zhang6, Erin Emme6, Carolyn M Mazure2,3, Sherry A McKee2,3. 1. Community Health and Social Medicine, Sophie Davis School of Biomedical Education/CUNY School of Medicine, New York, NY. 2. Department of Psychiatry, Yale University School of Medicine, New Haven, CT. 3. Women's Health Research at Yale, Yale University School of Medicine, New Haven, CT. 4. Ferkauf Graduate School of Psychology, Yeshiva University, New York, NY. 5. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY. 6. Department of Biostatistics, Yale University School of Public Health, New Haven, CT.
Abstract
INTRODUCTION: Converging clinical and biological evidence suggest sex is an important factor when selecting a pharmacological intervention for smoking cessation. The current investigation used network meta-analyses to estimate sex differences in the comparative efficacy of transdermal nicotine (TN), varenicline, and sustained release (SR) bupropion for smoking cessation. METHODS: Systematically searched previously published reviews and databases (Medline, PsycINFO, Embase) of randomized, double-blind, placebo-controlled trials of bupropion-SR, TN, and varenicline for cigarette smoking cessation in primary care/general community samples were included. RESULTS: Thirty-two studies met all criteria and 28 (88%) were included in the final analyses, representing 14 389 smokers (51% female). Results of the full sample (women and men combined) mirrored those from a Cochrane Tobacco Addiction Group network meta-analysis of smoking cessation pharmacotherapy, showing VAR>TN=BUP. All medications improved quit rates over placebo for both women and men. Relative to placebo, varenicline efficacy was similar for women and men. Significant sex differences were evident when comparing varenicline versus TN and varenicline versus bupropion. For women, varenicline was more efficacious than TN (RR = 1.41; 95% CI = 1.12,1.76) and bupropion (RR = 1.38; 95% CI = 1.08,1.77). For men, outcomes for those treated with TN and bupropion were similar to those treated with varenicline. There were no differences in efficacy when comparing bupropion versus TN. CONCLUSIONS: The advantage of varenicline over bupropion SR and TN is greater for women than men. Clinicians should strongly consider varenicline as the first option treatment for women. Among men, the advantage of varenicline over TN or bupropion is less clear. IMPLICATIONS: This study provides information for the sex-informed treatment of nicotine addiction among cigarette smokers. Relative to placebo, women and men achieved similar outcomes when treated with varenicline; however the advantages of varenicline over transdermal patch and bupropion were greater for women compared to men.
INTRODUCTION: Converging clinical and biological evidence suggest sex is an important factor when selecting a pharmacological intervention for smoking cessation. The current investigation used network meta-analyses to estimate sex differences in the comparative efficacy of transdermal nicotine (TN), varenicline, and sustained release (SR) bupropion for smoking cessation. METHODS: Systematically searched previously published reviews and databases (Medline, PsycINFO, Embase) of randomized, double-blind, placebo-controlled trials of bupropion-SR, TN, and varenicline for cigarette smoking cessation in primary care/general community samples were included. RESULTS: Thirty-two studies met all criteria and 28 (88%) were included in the final analyses, representing 14 389 smokers (51% female). Results of the full sample (women and men combined) mirrored those from a Cochrane Tobacco Addiction Group network meta-analysis of smoking cessation pharmacotherapy, showing VAR>TN=BUP. All medications improved quit rates over placebo for both women and men. Relative to placebo, varenicline efficacy was similar for women and men. Significant sex differences were evident when comparing varenicline versus TN and varenicline versus bupropion. For women, varenicline was more efficacious than TN (RR = 1.41; 95% CI = 1.12,1.76) and bupropion (RR = 1.38; 95% CI = 1.08,1.77). For men, outcomes for those treated with TN and bupropion were similar to those treated with varenicline. There were no differences in efficacy when comparing bupropion versus TN. CONCLUSIONS: The advantage of varenicline over bupropion SR and TN is greater for women than men. Clinicians should strongly consider varenicline as the first option treatment for women. Among men, the advantage of varenicline over TN or bupropion is less clear. IMPLICATIONS: This study provides information for the sex-informed treatment of nicotine addiction among cigarette smokers. Relative to placebo, women and men achieved similar outcomes when treated with varenicline; however the advantages of varenicline over transdermal patch and bupropion were greater for women compared to men.
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: Jill M Williams; Robert M Anthenelli; Chad D Morris; Joan Treadow; John R Thompson; Carla Yunis; Tony P George Journal: J Clin Psychiatry Date: 2012-05 Impact factor: 4.384
Authors: Robert M Anthenelli; Chad Morris; Tanya S Ramey; Sarah J Dubrava; Kostas Tsilkos; Cristina Russ; Carla Yunis Journal: Ann Intern Med Date: 2013-09-17 Impact factor: 25.391
Authors: John A Stapleton; Lucy Watson; Lucy I Spirling; Robert Smith; Andrea Milbrandt; Marina Ratcliffe; Gay Sutherland Journal: Addiction Date: 2007-11-19 Impact factor: 6.526
Authors: Sherry A McKee; Philip H Smith; Mira Kaufman; Carolyn M Mazure; Andrea H Weinberger Journal: Nicotine Tob Res Date: 2015-10-06 Impact factor: 4.244
Authors: Philip H Smith; Ju Zhang; Andrea H Weinberger; Carolyn M Mazure; Sherry A McKee Journal: Drug Alcohol Depend Date: 2017-07-10 Impact factor: 4.492
Authors: Angela M Lee; Cali A Calarco; Sherry A McKee; Yann S Mineur; Marina R Picciotto Journal: Genes Brain Behav Date: 2019-08-13 Impact factor: 3.449
Authors: Kimberly E Lind; Eric J Gutierrez; Dorothy J Yamamoto; Michael F Regner; Sherry A McKee; Jody Tanabe Journal: Drug Alcohol Depend Date: 2017-01-31 Impact factor: 4.492
Authors: Alicia M Allen; Nicole P Yuan; Betsy C Wertheim; Laurie Krupski; Melanie L Bell; Uma Nair Journal: Transl Behav Med Date: 2019-07-16 Impact factor: 3.046
Authors: Andrea H Weinberger; Philip H Smith; Allison P Funk; Shayna Rabin; Jonathan Shuter Journal: J Acquir Immune Defic Syndr Date: 2017-04-01 Impact factor: 3.731
Authors: Alicia M Allen; Andrea H Weinberger; Reagan R Wetherill; Carol L Howe; Sherry A McKee Journal: Nicotine Tob Res Date: 2019-04-17 Impact factor: 4.244
Authors: A Eden Evins; Neal L Benowitz; Robert West; Cristina Russ; Thomas McRae; David Lawrence; Alok Krishen; Lisa St Aubin; Melissa Culhane Maravic; Robert M Anthenelli Journal: J Clin Psychopharmacol Date: 2019 Mar/Apr Impact factor: 3.153
Authors: Krysten W Bold; Allen Zweben; Lisa M Fucito; Mary E Piepmeier; Srinivas Muvvala; Ran Wu; Ralitza Gueorguieva; Stephanie S O'Malley Journal: Alcohol Clin Exp Res Date: 2019-03-21 Impact factor: 3.455
Authors: Nicole L Tosun; Ann M Fieberg; Lynn E Eberly; Katherine A Harrison; Angela R Tipp; Alicia M Allen; Sharon S Allen Journal: Addiction Date: 2019-06-17 Impact factor: 6.526